TNGX Stock — Tango Therapeutics Inc.: Cash, EV, Pipeline

What they do

We leverage our state-of-the-art target and drug discovery platforms to identify novel disease-relevant targets and develop medicines tailored to defined patient populations with high unmet medical need. Our novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells.

Source: 10-K FY2025 via SEC EDGAR

Share price

$21.50

Market cap

$3,625.1M

Cash

$1,014.0M

Enterprise value

$2,611.1M

Balance sheet

Cash	$1,014.0M
Debt	$0.0M
Net cash	$1,014.0M
Enterprise value	$2,611.1M
Basic shares	169.9M shares
Fully diluted shares	196.0M shares
Fully diluted market cap	$4,214.8M
Cash per share	$5.97
Quarterly burn	$38.9M
Cash runway	26.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

169.9M

Pre-funded warrants

0.0M

Options

20.5M

RSUs

1.3M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

4.4M

FDSO

196.0M

Cap table as of 2025-12-31.

Price history

Loading TNGX daily closes…

Loading price history…

Next catalyst

TNG260 · Now - Nov 24, 2026 Now · Phase 2 · Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	TNG260	Phase 2	Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer	—
GUIDEDEst. Nov 7, 2026 Now half midpoint	TNG456 Phase 1/2 of TNG456 (brain-penetrant MTAP-selective PRMT5 inhibitor) in glioblastoma and other cancers	Phase 1/2	glioblastoma and other cancers	2H 2026
May 12 - Jun 23 in 6 mo	TNG456	Phase 2	Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant	—
Jun 12 - Jul 24 in 7 mo	S095035	Phase 2	MTAP-deleted Solid Tumors	—
Jul 13 - Aug 24 in 8 mo	TNG462	Phase 2	Locally Advanced Solid Tumor	—
Jul 13 - Aug 24 in 8 mo	TNG462	Phase 2	PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

vopimetostat

Phase 1 · Active Modality: small molecule (MTA-cooperative PRMT5 inhibitor; MTAP-deletion synthetic lethal)

Aliases TNG462

Target PRMT5

Partnerships Revolution Medicines: Nov 2024 CTCSA (daraxonrasib + zoldonrasib supply for vopimetostat combo; Tango sponsors; non-exclusive). Erasca: Mar 2026 CTCSA (ERAS-0015 supply for vopimetostat + ERAS-0015 Phase 1/2; Tango sponsors; non-exclusive)

Indications

MTAP-deleted pancreatic cancer (monotherapy and RAS-inhibitor combos) (Phase 1)
MTAP-deleted lung cancer (Phase 1)
MTAP-deleted cancers, histology-selective (excluding sarcoma, pancreatic, lung) (Phase 1)

Catalysts

— 2026
— 2026
— H2 2026

Status note Phase 1/2 ongoing; 2L pivotal trial in MTAP-deleted pancreatic cancer planned for 2026; registrational path for vopimetostat + daraxonrasib under development with Revolution Medicines.

TNG456

Phase 1 · Active Modality: small molecule (brain-penetrant MTA-cooperative PRMT5 inhibitor)

Target PRMT5

Indications

MTAP-deleted solid tumors, including glioblastoma (Phase 1)

Catalysts

— 2026

Status note First patient treated May 2025; dose escalation enrolling.

TNG961

Preclinical · Active Modality: small molecule (molecular glue degrader of HBS1L)

Target HBS1L

Indications

FOCAD-deleted/MTAP-deleted solid tumors (Preclinical)

Status note Development candidate; IND-enabling phase.

TNG260

Phase 1 · Active Modality: small molecule (CoREST inhibitor)

Target CoREST

Indications

Checkpoint inhibitor-resistant STK11-mutant / KRAS wild-type NSCLC (in combination with pembrolizumab) (Phase 1)

Status note 80 mg QD selected for dose expansion, ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TNG260
Lead indication	Non Small Cell Lung Cancer
Lead phase	Phase 2
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06810544	Phase 2	Recruiting	Sponsor	TNGX	LLY	Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant	2H 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)
NCT05732831	Phase 2	Recruiting	Sponsor	TNGX	—	Locally Advanced Solid Tumor	—
NCT06922591	Phase 2	Recruiting	Sponsor	TNGX	—	PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC	—
NCT05887492	Phase 2	Active, not recruiting	Sponsor	TNGX	—	Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer	—
NCT06188702	Phase 2	Active, not recruiting	Collaborator	Servier Bio-Innovation LLC	—	MTAP-deleted Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Tango Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	13,900,620	+600,000	3.71%	2026-08-14
Boxer Capital	10,876,219	no change	25.61%	2026-08-14
Deerfield Management	4,190,611	+43,798	1.37%	2026-08-14
Perceptive Advisors	3,377,000	+2,568,847	1.64%	2026-08-14
Logos Global Management	2,850,000	-150,000	3.84%	2026-08-14
Vivo Capital	1,379,769	-775,011	3.94%	2026-08-14
Cormorant Asset Management	1,300,000	-125,000	2.08%	2026-08-14
Baker Bros. Advisors	333,333	+333,333	0.05%	2026-08-14
Sphera Biotech	254,250	-89,313	1.14%	2026-08-14
ADAR1 Capital Management	76,761	+26,761	0.11%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

TNGX — Tango Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

TNGX — Tango Therapeutics Inc.